Tuesday, October 16, 2012

Developer: Change Zoning from Single-family to MH | Daily ...

CapeGazette VillageSoup informs MHProNews from Georgetown, Delaware Captain?s Way Development LLC has requested a zoning change for a 155-acre parcel of land from single-family site built to manufactured home community. Developer Pret Dyer, saying it is an opportunity for Sussex County to achieve its affordable housing quota, also stated he will donate 26 acres to the Nature Conservancy to serve as a buffer from other properties. A neighborhood resident, decrying the need for more manufactured housing, said a nearby MHC has 39 vacancies. Noting 25 percent of Sussex residents live in manufactured housing, and over 55 percent of them live on leased land, Preter said many local people cannot afford single-family housing but can afford MH.

(Photo credit: Ron MacArthur/Cape Gazette?Rehoboth Shores, DE)

Categories: Business, Communities, Company News, Legal, Manufactured Homes, News Item, regulation, Zoning Tags: acre parcel, affordable housing, community developer, development llc, Georgetown Delaware, manufactured housing, mh, MHC, MHProNews, nature conservancy, neighborhood, parcel of land, preter, quota, single family, sussex, Sussex County, vacancies, villagesoup

Source: http://www.mhmarketingsalesmanagement.com/blogs/daily-business-news/developer-change-zoning-from-single-family-to-mh/

bain capital marines urinating haley barbour olivier martinez peoples choice awards 2012 ford recalls robert kardashian

Wednesday, October 10, 2012

2 US scientists win Nobel chemistry prize

Dr. Robert Lefkowitz of Duke University photographed in his lab on campus in Durham, N.C. in 1996. Lefkowitz along with American Brian Kobilka have won the 2012 Nobel Prize in chemistry it was announced early Wednesday morning Oct. 10, 2012. The Royal Swedish Academy of Sciences cited the two researchers Wednesday "for studies of G-protein-coupled receptors." (AP Photo/News & Observer file photo)

Dr. Robert Lefkowitz of Duke University photographed in his lab on campus in Durham, N.C. in 1996. Lefkowitz along with American Brian Kobilka have won the 2012 Nobel Prize in chemistry it was announced early Wednesday morning Oct. 10, 2012. The Royal Swedish Academy of Sciences cited the two researchers Wednesday "for studies of G-protein-coupled receptors." (AP Photo/News & Observer file photo)

FILE - Dr. Robert Lefkowitz, of Duke University Medical Center, one of three winners of the Albany Medical Center Prize in Medicine and Biomedical Research, listens to remarks at a news conference at Albany Medical Center in Albany, N.Y., in this April 26, 2007 file photo. Lefkowitz along with American Brian Kobilka have won the 2012 Nobel Prize in chemistry it was announced early Wednesday morning Oct. 10, 2012. The Royal Swedish Academy of Sciences cited the two researchers Wednesday "for studies of G-protein-coupled receptors." (AP Photo/Tim Roske, File)

FILE - Dr. Robert Lefkowitz, of Duke University Medical Center, one of three winners of the Albany Medical Center Prize in Medicine and Biomedical Research, listens to remarks at a news conference at Albany Medical Center in Albany, N.Y., in this April 26, 2007 file photo. Lefkowitz along with American Brian Kobilka have won the 2012 Nobel Prize in chemistry it was announced early Wednesday morning Oct. 10, 2012. The Royal Swedish Academy of Sciences cited the two researchers Wednesday "for studies of G-protein-coupled receptors." (AP Photo/Tim Roske, File)

This image made available by the Swedish Academy of Sciences in Stockholm, Sweden Wednesday Oct. 10, 2012 shows Americans Robert Lefkowitz and Brian Kobilka who won the 2012 Nobel Prize in chemistry Wednesday for studies of proteins that let body cells respond to signals from the outside. The Royal Swedish Academy of Sciences said the two researchers had made groundbreaking discoveries on an important family of receptors, known as G-protein-coupled receptors. (AP Photo/Scanpix/Swedish Academy of Sciences, HO) (AP Photo/Handout)

(AP) ? Two American researchers won the Nobel Prize in chemistry Wednesday for studies of protein receptors that let body cells sense and respond to outside signals like danger or the flavor of food. Such studies are key for developing better drugs.

The Royal Swedish Academy of Sciences said Robert Lefkowitz and Brian Kobilka had made groundbreaking discoveries, mainly in the 1980s, on an important family of receptors, known as G-protein-coupled receptors.

About half of all medications act on these receptors, including beta blockers and antihistamines, so learning about them will help scientists to come up with better drugs.

The human body has about 1,000 kinds of such receptors, structures on the surface of cells, which let the body respond to a wide variety of chemical signals, like adrenaline. Some receptors are in the nose, tongue and eyes, and let us sense smells, tastes and light.

"They work as a gateway to the cell," Lefkowitz told a news conference in Stockholm by phone. "As a result they are crucial ... to regulate almost every known physiological process with humans."

Lefkowitz, 69, is an investigator at the Howard Hughes Medical Institute and professor at Duke University Medical Center in Durham, North Carolina.

Kobilka, 57, worked for Lefkowitz at Duke before transferring to Stanford University School of Medicine in California, where he is now a professor.

Lefkowitz said he was fast asleep when the Nobel committee called, but he didn't hear it because he was wearing ear plugs. So his wife picked up the phone.

"She said, 'There's a call here for you from Stockholm,'" Lefkowitz told The Associated Press. "I knew they ain't calling to find out what the weather is like in Durham today."

He said he didn't have an "inkling" that he was being considered for the Nobel Prize.

"Initially, I expected I'd have this huge burst of excitement. But I didn't. I was comfortably numb," Lefkowitz said.

Kobilka said he found out around 2:30 a.m., after the Nobel committee called his home twice. He said he didn't get to the phone the first time, but that when he picked up the second time, he spoke to five members of the committee.

"They passed the phone around and congratulated me," Kobilka told AP. I guess they do that so you actually believe them. When one person calls you, it can be a joke, but when five people with convincing Swedish accents call you, then it isn't a joke."

He said he would put his half of the 8 million kronor ($1.2 million) award toward retirement or "pass it on to my kids."

The academy said it was long a mystery how cells interact with their environment and adapt to new situations, such as when they react to adrenaline by increasing blood pressure and making the heart beat faster.

Scientists suspected that cell surfaces had some type of receptor for hormones.

Using radioactivity, Lefkowitz managed to unveil receptors including the receptor for adrenaline, and started to understand how it works.

Kobilka and his team realized that there is a whole family of receptors that look alike ? a family that is now called G-protein-coupled receptors.

In 2011, Kobilka achieved another breakthrough when his team captured an image of the receptor for adrenaline at the moment when it is activated by a hormone and sends a signal into the cell. The academy called the image "a molecular masterpiece."

The award is "fantastic recognition for helping us further understand the intricate details of biochemical systems in our bodies," said Bassam Z. Shakhashiri, president of the American Chemical Society.

"They both have made great contributions to our understanding of health and disease," Shakhashiri said. "This is going to help us a great deal to develop new pharmaceuticals, new medicines for combating disease."

Mark Downs, chief executive of Britain's Society of Biology, said the critical role receptors play is now taking for granted.

"This groundbreaking work spanning genetics and biochemistry has laid the basis for much of our understanding of modern pharmacology as well as how cells in different parts of living organisms can react differently to external stimulation, such as light and smell, or the internal systems which control our bodies such as hormones," Downs said in a statement.

The U.S. has dominated the Nobel chemistry prize in recent years, with American scientists being included among the winners of 17 of the past 20 awards.

This year's Nobel announcements started Monday with the medicine prize going to stem cell pioneers John Gurdon of Britain and Japan's Shinya Yamanaka. Frenchman Serge Haroche and American David Wineland won the physics prize Tuesday for work on quantum particles.

The Nobel Prizes were established in the will of 19th-century Swedish industrialist Alfred Nobel, the inventor of dynamite. The awards are always handed out on Dec. 10, the anniversary of Nobel's death in 1896.

___

AP Science Writer Malcolm Ritter in New York and AP writers Amanda Kwan in Phoenix, Jack Jones in Columbia, South Carolina, and Danica Kirka in London contributed to this report.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/3d281c11a96b4ad082fe88aa0db04305/Article_2012-10-10-Nobel-Chemistry/id-7887fea7559545778cb46e5b35013bdb

tim tebow taylor swift post grad arpaio carol burnett neil degrasse tyson neil degrasse tyson davy jones death

Tuesday, October 9, 2012

APNewsBreak: Raese built golf club without permits (The Arizona Republic)

Share With Friends: Share on FacebookTweet ThisPost to Google-BuzzSend on GmailPost to Linked-InSubscribe to This Feed | Rss To Twitter | Politics - Top Stories Stories, News Feeds and News via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/253984533?client_source=feed&format=rss

danny gokey sonny rollins sweet caroline lottery winning numbers pro bowl roster quirky chrissy teigen

Google wants developers to start building quality tablet apps

Android Central

With the launch and relative success of the Nexus 7 -- and other popular large tablets -- it's apparent that Google is trying to take Android tablets seriously. One sticking point with Android on larger screens though was the conflict between having separate tablet apps, scaled-up phone apps or universal binaries that can handle all screen sizes. Today on the Android Developers Blog, Google is highlighting several points that Android developers should keep in mind when getting their apps ready for use on tablets.

As a follow-up to previous pushes for better design, these latest guidelines help developers manage making apps look better on large screens by recommending ways to make the app scale properly, make use of the extra screen real estate and improve graphics for tablets. In the post, popular tablet-optimized apps from Mint.com, TinyCo and Instapaper are highlighted as good examples of what developers should be trying to do with their app designs.

The idea of having a single app available in Google Play that scales and changes based on the device is a very compelling one, provided that developers do a good job of managing those different screen sizes. It's good to see that the Android team is doing what it can to help along the process.

Source: Android Developers Blog



Source: http://feedproxy.google.com/~r/androidcentral/~3/Bdd8Xy2CnPQ/story01.htm

daytona race the cutting edge fox 8 news indy 500 angelina jolie leg daytona jeff gordon

India Ratings Publishes Downgrades of SREI Finance ? World ...

India Ratings Publishes Downgrades of SREI Finance

The legal tussle between Kolkata-based Srei Infrastructure Finance and India Ratings (formerly Fitch Ratings India) may refuse to die over the rating agency?s move to downgrade the company?s ratings.

After a go-ahead by the Calcutta High Court and market regulator SEBI, India Ratings today put in public domain downgrade of ratings of Srei Infrastructure Finance.

The company said it will again approach Calcutta High Court and accused India Ratings of acting in haste and basing ratings on ?inaccurate conjecture?.

India Ratings cut both long term and short term ratings of the company by a notch, but still these remain within investment grade. While the long term rating of the company was downgraded to IND A + from IND AA-, short term rating was reduced to IND A1 from IND A1+. The outlook on long term rating was negative at the time of the downgrade.

The rating downgrade was originally done way back on March 19 this year, but was withheld from public domain after Srei Infrastructure Finance got a stay order from Calcutta High Court. Meanwhile, Srei Infrastructure Finance terminated its contract with India Ratings.

Later in September, Calcutta High Court allowed India Ratings to go ahead with releasing the downgrade, subject to satisfaction by market regulator SEBI that the rating agency has adhered to norms and regulations.

Sebi had yesterday informed India Ratings that the rating action by India Ratings is generally conforming to the SEBI (Credit Rating Agencies) Regulations, 1999, the rating agency officials said.

As such, the company put its ratings in public domain.

?As per the Honourable High Court?s order, India Ratings is no longer constrained in publishing the decision of the rating committee held on 19 March 2012,? the rating agency said in a statement here.

The statement said the rating downgrade reflected elevated credit risk in Srei Infrastructure Finance loans due to its largely unseasoned portfolio resulting from its continuous high loan growth, especially in the financial year ended March 2011 (FY11) and the first nine months of 2011-12.

?A large proportion of Srei Infrastructure Finance equity is locked up in unlisted investments, leaving the company with limited capital to cushion losses from elevated loans in the event of stress,? it said.

The downgrade of the Short-term rating also factors in Srei Infra?s higher reliance on short-term and working capital funding, compared with ?IND A1+?- rated non-banking finance companies, for financing infrastructure loans, the statement said.

The rating agency said it is unable to comment on the present rating level given that no information has been shared by Srei Infra, post the last review.

As such, it recommended investor caution, given that the negative outlook implies potential for a further rating downgrade.

Shashi? Bhushan Tiwari, Chief Operating Officer, Srei Infrastructure Finance Limited, told Business Standard,?Fitch has acted in haste and their view is based on inaccurate conjecture. We are going to represent this matter to the Hon?ble High Court,Calcutta.?

On the other hand, Ananda Bhoumik, senior director with India Ratings, said,? We are pleased that our independence as a rating agency is upheld. We believe it is very positive for the markets and for investors.?

The company finances infrastructure projects, infrastructure development, large infrastructure equipment, and provides advisory services in the infrastructure financing space. The company is also joint-owner, along with BNP Paribas Leasing Solutions, of Srei Equipment Finance, India?s leading equipment finance company.

SOURCE

Source: http://www.worldleasingnews.com/news/india-ratings-publishes-downgrades-of-srei-finance/

Alex Morgan Misty May Treanor Lolo Jones Aly Raisman Marvin Hamlisch Megan Rossee NASA

First successful clinical trial to protect the brain from damage caused by stroke

ScienceDaily (Oct. 8, 2012) ? A team of Canadian scientists and clinicians, led by Dr. Michael Hill of the Calgary Stroke Program at Foothills Medical Centre and University of Calgary's Hotchkiss Brain Institute (HBI), have demonstrated that a neuroprotectant drug, developed by Dr. Michael Tymianski at the Krembil Neuroscience Centre, located at the Toronto Western Hospital, protects the human brain against the damaging effects of stroke.

The study, "Safety and efficacy of NA-1 for neuroprotection in iatrogenic stroke after endovascular aneurysm repair: a randomized controlled trial," published online October 8 in The Lancet Neurology, was conducted concurrently with a laboratory study published in Science Translational Medicine, that predicted the benefits of the stroke drug.

This landmark clinical trial was a randomized, double blinded, multi-centre trial that was conducted in Canada and the USA. The study evaluated the effectiveness of NA-1[Tat-NR2B9c] when it was administered after the onset of small strokes that are incurred by patients who undergo neurointerventional procedures to repair brain aneurysms. This type of small ischemic stroke occurs in over 90% of aneurysm patients after such a procedure, but usually does not cause overt neurological disability.

In the clinical trial, patients were randomized to receive either Tat-NR2B9c or placebo. Those treated with Tat-NR2B9c showed a reduction in the amount of brain damage sustained as a result of the aneurysm repair procedure. Also, in patients who had ruptured brain aneurysm, which comprise a population of patients at very high risk of neurological damage, those treated with Tat-NR2B9c all had good neurological outcomes, whereas only 68% of those treated with placebo had good outcomes.

"The results of this clinical trial represent a major leap forward for stroke research," said Dr. Hill. "There have been over 1,000 attempts to develop such drugs, which have failed to make the leap between success in the lab and in humans."

"This clinical trial is, to our knowledge, the first time that a drug aimed at increasing the resistance of the brain to stroke, has been shown to reduce stroke damage in humans. No efforts should be spared to develop it further," said Dr. Michael Tymianski, who oversaw the development of Tat-NR2B9c from its invention in his lab, through to clinical trials.

Currently, t-PA is the only widely approved acute stroke therapy. It works by unblocking the arteries to the brain, however, this treatment is only beneficial for a portion of stroke victims. It also has serious potential for side-effects, including bleeding in the brain.

"Through our lab research and clinical trial, we now have a better method of predicting whether a stroke drug may be effective in humans and we now have the evidence that there is a neuroprotectant that can prevent damage in the brain caused by reduced blood flow," said Dr. Tymianski, inventor of NA-1 and one of the study's authors. "The benefits of this can be explored not only for stroke, but for other conditions such as vascular dementia."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by University Health Network (UHN), via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Michael D Hill, Renee H Martin, David Mikulis, John H Wong, Frank L Silver, Karel G terBrugge, Genevi?ve Milot, Wayne M Clark, R Loch MacDonald, Michael E Kelly, Melford Boulton, Ian Fleetwood, Cameron McDougall, Thorsteinn Gunnarsson, Michael Chow, Cheemun Lum, Robert Dodd, Julien Poublanc, Timo Krings, Andrew M Demchuk, Mayank Goyal, Roberta Anderson, Julie Bishop, David Garman, Michael Tymianski. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 2012; DOI: 10.1016/S1474-4422(12)70225-9

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/health_medicine/genes/~3/1N5lXjXaOsg/121008091454.htm

marlon byrd charles colson humber raffi torres michael mcdonald jon jones vs rashad evans earth day 2012

10.18 - College Admissions Essay Workshop at MTPL

Sorry, Readability was unable to parse this page for content.

Source: http://calendar.redbankgreen.com/events/index.php?com=detail&eID=25363

super bowl matthew broderick tax refund calculator huntington disease west memphis three taxes game of thrones season 2 trailer